Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
US Market

Day One Biopharmaceuticals Income Statement

45 Followers

Day One Biopharmaceuticals Income Statement

Last quarter (Q3 2022), Day One Biopharmaceuticals's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Day One Biopharmaceuticals's net income was $-37.80M. See Day One Biopharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19
Total Revenue
-$ 0.00$ 0.00$ 0.00
Cost of Revenue
----
Gross Profit
----
Operating Expense
$ 126.14M$ 72.74M$ 13.78M$ 14.90M
Operating Income
$ -126.14M$ -72.74M$ -13.78M$ -14.90M
Net Non Operating Interest Income Expense
$ 2.11M$ 4.00K$ -30.00K$ -2.08M
Other Income Expense
$ 22.00K$ -15.00K$ -30.03M$ -2.00K
Pretax Income
$ -124.01M$ -72.75M$ -43.84M$ -16.98M
Tax Provision
----
Earnings From Equity Interest Net Of Tax
----
Net Income Common Stockholders
$ -124.01M$ -170.64M$ -40.51M$ -12.63M
Basic EPS
$ -1.96$ -4.62$ -0.54$ -0.49
Diluted EPS
$ -1.96$ -4.62$ -0.54$ -0.49
Basic Average Shares
$ 252.10M$ 36.96M$ 25.65M$ 25.65M
Diluted Average Shares
$ 252.10M$ 36.96M$ 25.65M$ 25.65M
Dividend Per Share
----
Total Operating Income As Reported
----
Reported Normalized Basic E P S
----
Reported Normalized Diluted E P S
----
Rent Expense Supplemental
----
Total Expenses
$ 126.14M$ 72.74M$ 13.78M$ 14.90M
Net Income From Continuing And Discontinued Operation
$ -124.01M$ -70.64M$ -40.51M$ -12.63M
Normalized Income
$ -124.01M$ -70.64M$ -10.51M$ -12.63M
Interest Expense
--$ 30.00K$ 2.08M
EBIT
$ -126.11M$ -72.74M$ -43.81M$ -14.91M
EBITDA
$ -125.71M$ -72.54M$ -43.66M$ -14.91M
Currency in USD

Day One Biopharmaceuticals Earnings and Revenue History


What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis